GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iZafe Group AB (OSTO:IZAFE B) » Definitions » EV-to-EBITDA

iZafe Group AB (OSTO:IZAFE B) EV-to-EBITDA : -6.07 (As of Jun. 30, 2025)


View and export this data going back to 2011. Start your Free Trial

What is iZafe Group AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, iZafe Group AB's enterprise value is kr81.67 Mil. iZafe Group AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was kr-13.45 Mil. Therefore, iZafe Group AB's EV-to-EBITDA for today is -6.07.

The historical rank and industry rank for iZafe Group AB's EV-to-EBITDA or its related term are showing as below:

OSTO:IZAFE B' s EV-to-EBITDA Range Over the Past 10 Years
Min: -43.61   Med: -5.31   Max: -0.84
Current: -6.07

During the past 13 years, the highest EV-to-EBITDA of iZafe Group AB was -0.84. The lowest was -43.61. And the median was -5.31.

OSTO:IZAFE B's EV-to-EBITDA is ranked worse than
100% of 498 companies
in the Medical Devices & Instruments industry
Industry Median: 15.41 vs OSTO:IZAFE B: -6.07

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2025-06-30), iZafe Group AB's stock price is kr0.249. iZafe Group AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was kr-0.070. Therefore, iZafe Group AB's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


iZafe Group AB EV-to-EBITDA Historical Data

The historical data trend for iZafe Group AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iZafe Group AB EV-to-EBITDA Chart

iZafe Group AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -14.20 -1.53 -3.21 -5.51 -4.10

iZafe Group AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.03 -4.76 -4.37 -4.10 -6.23

Competitive Comparison of iZafe Group AB's EV-to-EBITDA

For the Medical Instruments & Supplies subindustry, iZafe Group AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iZafe Group AB's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iZafe Group AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where iZafe Group AB's EV-to-EBITDA falls into.


;
;

iZafe Group AB EV-to-EBITDA Calculation

iZafe Group AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=81.670/-13.445
=-6.07

iZafe Group AB's current Enterprise Value is kr81.67 Mil.
iZafe Group AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-13.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iZafe Group AB  (OSTO:IZAFE B) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

iZafe Group AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.249/-0.070
=At Loss

iZafe Group AB's share price for today is kr0.249.
iZafe Group AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-0.070.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


iZafe Group AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of iZafe Group AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


iZafe Group AB Business Description

Traded in Other Exchanges
Address
David Bagares Gata 3, Stockholm, SWE, 111 38
iZafe Group AB is a pure Life-Science company engaged in the development of digital drug dispensing. The company conducts research, development and marketing of digital medical solutions and services for safer drug management at home. iZafe's drug robot Dosell is used to reduce the risk of incorrect medication at home, relieve public care, increase the patient's quality of life and create a safer environment for relatives. The customers consist of public and private care providers in Sweden, the Nordic countries and globally. iZafe sells through well-established partners who already have long and deep customer relationships with the priority customer groups.

iZafe Group AB Headlines

No Headlines